Advertisement

Topics

Synergy Pharmaceuticals, Inc. Company Profile

14:57 EDT 15th October 2018 | BioPortfolio

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's proprietary drug SP-304 is a synthetic analog of the human gastrointestinal hormone uroguanylin, and acts by activating the guanylate cyclase C (GC-C) receptor on epithelial cells of the GI tract. SP-304 has completed a Phase I clinical trial in volunteers and is presently in a Phase 2a clinical trial of SP-304 in patients to treat chronic constipation. The Company expects to obtain topline data from this trial in 2010, and use those data to begin a Phase 2b 28-day repeated-oral-dose, placebo-controlled trial in SP-304 in CC patients in early 2011 and a Phase 2b 90-day repeated-oral-dose, placebo-controlled trial of SP-304 in IBS-C patients in the second quarter of 2011. More information is available at http://www.synergypharma.com.


News Articles [506 Associated News Articles listed on BioPortfolio]

Synergy Pharmaceuticals Announces License Agreement with Luoxin Pharmaceutical Group for TRULANCE (plecanatide) in China

Synergy Pharmaceuticals (NASDAQ:SGYP) announced today that the company has entered into a license agreement with Luoxin Pharmaceutical Group Shandong (Luoxin) providing Luoxin exclusive rights to deve...

The Klein Law Firm Reminds Investors of Commencement of Class Actions on Behalf of Synergy Pharmaceuticals Inc. Shareholders and a Lead Plaintiff Deadline of April 10, 2018

NEW YORK, NY / ACCESSWIRE / April 3, 2018 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) who pu...

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm

LOS ANGELES, CA / ACCESSWIRE / April 10, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Synergy Pharmaceuticals In...

DEADLINE APPROACHING: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $100,000 To Contact The Firm

LOS ANGELES, CA / ACCESSWIRE / April 2, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Synergy Pharmaceuticals Inc...

DEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $100,000 To Contact The Firm

LOS ANGELES, CA / ACCESSWIRE / April 7, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Synergy Pharmaceuticals Inc...

APRIL 10 DEADLINE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $100,000 To Contact The Firm

LOS ANGELES, CA / ACCESSWIRE / March 28, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Synergy Pharmaceuticals In...

5-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $100,000 To Contact The Firm

LOS ANGELES, CA / ACCESSWIRE / April 5, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Synergy Pharmaceuticals Inc...

7-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $100,000 To Contact The Firm

LOS ANGELES, CA / ACCESSWIRE / April 3, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Synergy Pharmaceuticals Inc...

Drugs and Medications [274 Associated Drugs and Medications listed on BioPortfolio]

Endure 200 [Ecolab Inc.]

Drug Facts

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash

Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

Antacid [Major Pharmaceuticals]

Major Pharmaceuticals Antacid Tablets Drug Facts

PubMed Articles [241 Associated PubMed Articles listed on BioPortfolio]

The cooperation of pharmacologic-dose ascorbate with ceftriaxone against Staphylococcus aureus through bactericidal synergy and enhanced macrophage killing activity.

Ascorbate is a low-cost compound with a known bactericidal-synergy to antibitics. However, the synergy depends on concentrations and organisms. Thus, the synergy test by time-kill assay might be appro...

Swimming activity in zebrafish larvae exposed to veterinary antiparasitic pharmaceuticals.

Veterinary antiparasitic pharmaceuticals have been detected in surface waters and several of these pharmaceuticals act on the nervous system on the target organisms implying that neurological effects ...

Chiral pharmaceuticals: Environment sources, potential human health impacts, remediation technologies and future perspective.

Chiral pharmaceuticals (CPs), including non-steroid anti-inflammatory drugs (NSAIDs), β-blockers and some herbicide and pesticides, are widely used in aquaculture, clinical treatment and many other f...

Assessment of 83 pharmaceuticals in WWTP influent and effluent samples by UHPLC-MS/MS: Hourly variation.

The removal efficiency of pharmaceuticals in wastewater treatment plants (WWTPs) is variable and some of these compounds pass these plants almost intact and others presenting a removal efficiency clos...

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Clinical Trials [312 Associated Clinical Trials listed on BioPortfolio]

A 2x2 Factorial Randomized Controlled Trial of Colchicine and Spironolactone in Patients With STEMI Who Have Undergone PCI With SYNERGY Stent Registry

The CLEAR SYNERGY trial will study the long term effects of three multidisciplinary treatments following PCI to treat ST elevation myocardial infarction. These treatments address both the ...

IRIS-Synergy Cohort in the IRIS-DES Registry

The purpose of this study is to evaluate the relative effectiveness and safety of Synergy stent compared to other drug eluting stents.

Safety and Performance Evaluation of CircuLite Synergy

The purpose of the study is to demonstrate the safety and functionality of the CircuLite Synergy Pocket Circulatory Assist Device.

Registry Experience at the Washington Hospital Center With Drug Eluting Stents - Synergy

To compare the incidence of major adverse cardiac events among a series of patients receiving the Synergy drug-eluting stent with bioabsorbable polymer to historical controls who have rece...

SYNERGY China: Assess SYNERGY Stent in China

Prospective, multicenter, single-arm study, enroll 100 patients in no more than 10 sites across China, the primary endpoint is Technical success.

Companies [1378 Associated Companies listed on BioPortfolio]

Synergy Pharmaceuticals, Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's proprietary drug SP-304 is a synthetic a...

Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of new drugs to treat patients with gastrointestinal (GI) diseases and disorders. Synergyâ...

Synergy Health Concepts

The team at Pacific Interventionalists launched Synergy Health Concepts to focus specifically on CCSVI treatment and care. Chronic Cerebro-Spinal Venous Insufficiency (CCSVI) is c...

Synergy Strips Corp.

Synergy Strips Corp. (OTCQB:SNYR) is a consumer health care company, that is in the process of building a portfolio of best-in- class consumer product brands. Synergy's strategy i...

BIND Therapeutics and Synergy Pharmaceuticals

More Information about "Synergy Pharmaceuticals, Inc." on BioPortfolio

We have published hundreds of Synergy Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of Synergy Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about Synergy Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Synergy Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant Synergy Pharmaceuticals, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Endocrinology
Diabetes Diabetes Endocrine Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several groups of h...


Corporate Database Quicklinks



Searches Linking to this Company Record